CSF2 and autoimmune pulmonary alveolar proteinosis: While in autoimmune PAP there are anti GM-CSF antibodies and therefore GM-CSF administration is a promising pharmacotherapeutic approach [11]; research in LPI could not justify the role of GM-CSF administration since in LPI GM-CSF signaling pathway was found to be unaltered [12].